Share on StockTwits

Tornier NV (NASDAQ:TRNX) has been given an average recommendation of “Buy” by the eight ratings firms that are currently covering the company, American Banking News.com reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $21.00.

Tornier NV (NASDAQ:TRNX) traded up 12.57% on Friday, hitting $21.94. 126,674 shares of the company’s stock traded hands. Tornier NV has a 52-week low of $15.17 and a 52-week high of $24.35. The stock’s 50-day moving average is $22.29 and its 200-day moving average is $20.51. The company’s market cap is $1.065 billion.

Tornier NV (NASDAQ:TRNX) last announced its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.04. The company had revenue of $86.85 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, analysts predict that Tornier NV will post $-0.45 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on TRNX shares. Analysts at BMO Capital Markets upgraded shares of Tornier NV from a “market perform” rating to an “outperform” rating in a research note on Friday. They now have a $24.00 price target on the stock, up previously from $20.00. Separately, analysts at TheStreet upgraded shares of Tornier NV from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. Finally, analysts at Barclays raised their price target on shares of Tornier NV from $23.00 to $26.00 in a research note on Thursday, June 5th. They now have an “overweight” rating on the stock.

Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.

Receive News & Ratings for Tornier NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tornier NV and related companies with Analyst Ratings Network's FREE daily email newsletter.